world-biomarkers-pharma-biotech-2017-tracks

25 / 28

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 53
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Novel biomarker proteins for cancer: Impact on diagnosis, prognosis and treatment
Varda Shoshan Barmatz
NIBN- Ben-Gurion University of the Negev, Israel
C ancer cells undergo re-programing of metabolism, cell survival and anti-apoptotic defenses, with the proteins mediating these
re-programing representing potential biomarkers. Here, using specific antibodies, mass spectrometry and bioinformatics tools;
we searched for novel biomarker proteins in chronic lymphocytic leukemia (CLL) and in non-small cell lung cancer (NSCLC) patient
samples that can impact diagnosis, treatment and prognosis. By comparing protein expression profiles of CLL- and healthy donor-
derived lymphocytes, we identified 1,360 differentially expressed proteins, some shown for the first time to be associated CLL. Down-
regulated expression of two proteins resulted in cell growth inhibition, pointing to their essential functions. Based on changes in the
levels of several proteins in CLL patients, we could distinguish between patients in a stable disease state and those who would be later
subjected to anti-cancer treatments, 2-3 years before the physician’s decision. In NSCLC, the adenocarcinoma (AC) and squamous
cell carcinoma (SCC), sub-types present unique genomes, transcriptomes, and proteomes, and share clinical and histopathological
characteristics, yet differ in treatment. We identified novel biomarker proteins in NSCLC, with 378 proteins showing a ≥|100|-fold
change in level. Several, identified for the first time, allow for distinguishing between AC and SCC. These, together with markers
previously proposed and confirmed here, lead us to propose a list of proteins for discriminating SCC and AC, with four being
secreted. Precise diagnosis of AC and SCC is essential for selecting appropriate treatment. Finally, some of these biomarkers can serve
as new targets and lead to new treatments for lung and CLL cancers.
Biography
Varda Shoshan Barmatz is the Hyman-Kreitman Chair in Bioenergetics at Ben-Gurion University (BGU). Her PhD is from the Weizmann Institute; Post-doctoral
training was from the University of Wisconsin-Madison and the University of Toronto. In 1982, she joined the Department of Life Sciences, BGU, and served as
Chair (2000-2004). Her awards include the Hestrin Prize of the Israel Biochemistry Society, Teva Award for Young Scientists (1993) and Teva Founders Award
(2016). Lady Globes magazine selected her as one of the 50 most influential women in Israel (2009) and one of five who made breakthroughs in science (2016).
She was the Founder and Director (2006-2015) of the National Institute for Biotechnology in the Negev.
Varda Shoshan Barmatz, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-109